2seventy Bio Shares Fall Premarket on Abecma Expansion Delay
By Colin Kellaher
Shares of 2seventy bio fell more than 10% Monday after the biotechnology company's efforts to win expanded U.S. approval for its Abecma gene therapy with Bristol Myers Squibb hit a delay.
Bristol Myers and 2seventy said the U.S. Food and Drug Administration won't meet its Dec. 16 target action date on the companies' application seeking approval of Abecma for earlier lines of triple-class exposed relapsed or refractory multiple myeloma after the agency opted to hold an advisory committee meeting.
Abecma is currently approved for adults after four or more prior lines of therapy.
2seventy and Bristol share equally in all profit and losses related to U.S. development, manufacture and commercialization of Abecma, which generated $302 million in U.S. commercial revenue in the first nine months of 2023.
Analysts at Citi last month initiated coverage of 2seventy bio with a buy rating and a $13 price target, saying they expected an FDA green light for using Abecma in earlier lines would create a capacity-constrained environment that will benefit the therapy.
2seventy shares, which closed Friday at $2.13, were recently down more than 10% at $1.91 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 20, 2023 08:15 ET (13:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing